2019年常兆华在股东大会上喊出“万亿市值”目标时,微创医疗正站在高光时刻:市值超千亿港元,骨科与心血管业务双翼齐飞,分拆上市的子公司如火箭般蹿升。仅仅五年后,这家曾经的明星企业却深陷债务泥潭——2024年初,7.43亿美元债务压顶,市值仅剩120亿港元,蒸发超过90%,最终通过“借新还旧”暂时化解。资本市场的热情消退后,留下的是一个需要解答的核心命题:这家曾对标美敦力的中国医疗器械巨头,能否在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.